Tecentriq Side Effects
Generic name: atezolizumab
Note: This document contains side effect information about atezolizumab. Some dosage forms listed on this page may not apply to the brand name Tecentriq.
Common side effects of Tecentriq include: herpes simplex encephalitis, infection, mycobacterium infection, retroperitoneal hemorrhage, sepsis, severe infection, urinary tract infection, colitis, diarrhea, and increased thyroid stimulating hormone level. Continue reading for a comprehensive list of adverse effects.
Applies to atezolizumab: parenteral injection.
Side effects include:
In combination with albumin-bound paclitaxel in patients with triple-negative breast cancer (≥20%): Alopecia, peripheral neuropathy, fatigue, nausea, diarrhea, constipation, cough, headache, vomiting, decreased appetite; laboratory abnormalities occurring in ≥50% of patients include decreased concentrations of hemoglobin, leukocytes, neutrophils, and lymphocytes.
In combination with cobimetinib and vemurafenib in patients with melanoma (≥20%): Rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, photosensitivity.
For Healthcare Professionals
Applies to atezolizumab: intravenous solution.
Very common (10% or more): Rash (15%), pruritus (13%)[Ref]
Very common (10% or more): Nausea (25%), constipation (21%), diarrhea (18%), abdominal pain (17%), vomiting (17%)
The most common adverse reactions (greater than 20%) were fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation. The most common Grade 3 to 4 adverse reactions (greater than 2%) were urinary tract infection, anemia, fatigue, dehydration, intestinal obstruction, urinary obstruction, hematuria, dyspnea, acute kidney injury, abdominal pain, venous thromboembolism, sepsis, and pneumonia.[Ref]
Very common (10% or more): Urinary tract infection (22%)
Common (1% to 10%): Urinary obstruction[Ref]
Common (1% to 10%): Anemia, lymphopenia, increased alkaline phosphatase, increased alkaline phosphatase[Ref]
Common (1% to 10%): Acute kidney injury, liver enzyme increase, increased ALT, increased AST
Very common (10% or more): Immune related colitis (19.7%)
Common (1% to 10%): Immune related pneumonitis, immune related hepatitis, sepsis
Frequency not reported: Immune related endocrinopathies[Ref]
Frequency not reported: Infusion related reactions[Ref]
Very common (10% or more): Decreased appetite (26%)
Very common (10% or more): Back/neck pain (15%), arthralgia (14%)[Ref]
Frequency not reported: Ocular inflammatory toxicity[Ref]
Very common (10% or more): Fatigue (52%), pyrexia (21%), peripheral edema (18%)
Common (1% to 10%): Increased creatinine[Ref]
Common (1% to 10%): Confusional state[Ref]
Common (1% to 10%): Hematuria[Ref]
Very common (10% or more): Dyspnea (16%), cough (14%)
Common (1% to 10%): Dyspnea, pneumonia[Ref]
Frequently asked questions
- What is the cost of Tecentriq?
- Is this a chemotherapy or immunotherapy drug?
- How effective is it?
- Does it cause hair loss?
- How is it administered?
- What type of cancer is Tecentriq used to treat?
More about Tecentriq (atezolizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (2)
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- En español
Related treatment guides
1. Cerner Multum, Inc. UK Summary of Product Characteristics.
2. Product Information. Tecentriq (atezolizumab). Genentech. 2016.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.